0000000000349698

AUTHOR

A Sigalas

showing 2 related works from this author

Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospecti…

2008

SUMMARY Pegylated interferon with ribavirin (Peg/R) is the most effective therapy for chronic hepatitis C virus (HCV) but its utility and effectiveness after liver transplantation has been difficult to assess. We evaluated efficacy, tolerability, and safety of Peg/R in liver transplant candidates and recipients with HCV cirrhosis. We searched medical databases and conference proceedings between January 1999 and January 2008 selecting randomized and nonrandomized studies. Primary end points meta-analytically were: (1) sustained viral response (SVR) and (2) histological response. Secondary end points were: (1) treatment discontinuation, (2) mortality, and (3) rejection episodes. Pegylated int…

Liver Cirrhosismedicine.medical_specialtyCirrhosismedicine.medical_treatmentHepacivirusPharmacologyLiver transplantationAntiviral AgentsGastroenterologyPolyethylene Glycolschemistry.chemical_compoundPegylated interferonVirologyInternal medicineRibavirinmedicineHumansProspective StudiesRandomized Controlled Trials as TopicClinical Trials as Topiccirrhosis HCV pegylated interferon ribavirin transplantation.Hepatologybusiness.industryRibavirinvirus diseasesmedicine.diseaseHepatitis CLiver TransplantationDiscontinuationTransplantationRegimenTreatment OutcomeInfectious DiseaseschemistryTolerabilityDrug Therapy CombinationInterferonsbusinessmedicine.drug
researchProduct

Models for non-alcoholic fatty liver disease: a link with vascular risk.

2008

Non alcoholic fatty liver disease (NAFLD) is often part of the metabolic syndrome which includes central obesity, dyslipidaemia, insulin resistance/type 2 diabetes mellitus and hypertension. In turn, NAFLD may be associated with an increased vascular risk. Several experimental models which express histological steatosis or steatohepatitis with fibrosis have been described. This review identifies those models of NAFLD with features of vascular risk.

medicine.medical_specialtyDiseasedigestive systemGastroenterologyInsulin resistanceNAFLD central obesity dyslipidaemia insulin resistance/type 2Risk FactorsInternal medicineDrug DiscoveryAnimalsHumansMedicineVascular DiseasesRisk factorPharmacologybusiness.industryFatty livernutritional and metabolic diseasesType 2 Diabetes Mellitusmedicine.diseasedigestive system diseasesFatty LiverDisease Models AnimalEndocrinologyInflammation MediatorsSteatosisMetabolic syndromeSteatohepatitisbusiness
researchProduct